ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.

HROW Harrow Inc

10,52
0,33 (3,24%)
Zuletzt aktualisiert: 21:17:06
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Harrow Inc HROW NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,33 3,24% 10,52 21:17:06
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
10,24 10,04 10,81 10,19
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
25.4.202413:00BWHarrow Will Release First Quarter 2024 Financial Results..
02.4.202414:16BWMelt Pharmaceuticals Closes $24 Million Series B Preferred..
20.3.202412:15IHMARKETNEWSJPMorgan boosts dividends, Chipotle unveils 50:1 stock..
19.3.202422:45BWHarrow Announces Fourth Quarter and Year-End 2023 Financial..
19.3.202412:27IHMARKETNEWSUS Index Futures Decline Ahead of Federal Reserve Meeting,..
06.3.202412:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.3.202413:00BWHarrow Will Release Fourth Quarter and Year-End 2023..
22.2.202401:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22.2.202401:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15.2.202422:15EDGAR2Form 8-K - Current report
15.2.202422:01BWHarrow Licenses Canadian Rights to Apotex for Five Branded..
09.2.202422:05EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08.2.202413:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29.1.202422:30EDGAR2Form 8-K - Current report
29.1.202421:26EDGAR2Form SC 13G - Statement of acquisition of beneficial..
29.1.202413:00BWHarrow Announces New Appointments to its Board of Directors
11.1.202413:00BWHarrow Announces Availability of VEVYE® (Cyclosporine..
09.1.202416:16EDGAR2Form SC 13G - Statement of acquisition of beneficial..
03.1.202414:00EDGAR2Form 8-K - Current report
03.1.202413:15BWMelt Pharmaceuticals Provides Corporate Update
03.1.202413:00BWHarrow Partners with Leading Healthcare Market Access..
29.11.202313:00BWHarrow Completes Transfer of the TRIESENCE® New Drug..
20.11.202313:00BWHarrow to Present at Two Investor Conferences in November
16.11.202322:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15.11.202301:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13.11.202322:38EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13.11.202322:34EDGAR2Form 8-K - Current report
13.11.202322:01BWHarrow Announces Third Quarter 2023 Financial Results
03.11.202321:52EDGAR2Form 8-K - Current report
30.10.202313:00BWHarrow Will Release Third Quarter 2023 Financial Results on..
24.10.202313:00BWHarrow Completes Transfer of NDAs and Launches FLAREX®,..
29.9.202322:01EDGAR2Form 8-K - Current report
29.9.202314:00BWHarrow Health, Inc. Changes Corporate Name to Harrow, Inc.
26.9.202314:00BWMelt Pharmaceuticals Announces Exclusive Development and..
21.9.202300:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15.8.202313:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09.8.202322:26EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09.8.202322:05EDGAR2Form 8-K - Current report
09.8.202322:01BWHarrow Announces Second Quarter 2023 Financial Results
31.7.202313:00BWHarrow Launches VIGAMOX® in the U.S.
26.7.202315:00BWHarrow to Announce Second Quarter 2023 Financial Results on..
21.7.202322:02EDGAR2Form 8-K - Current report
21.7.202301:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.7.202301:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19.7.202323:19EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
19.7.202313:00BWHarrow Prices $60 Million Public Offering of Common Stock
19.7.202304:55BWHarrow erwirbt US-amerikanische und kanadische..
18.7.202323:03EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
18.7.202323:00BWHarrow Acquires Santen’s Branded Ophthalmic Portfolio
18.7.202322:59EDGAR2Form 8-K - Current report

Kürzlich von Ihnen besucht

Delayed Upgrade Clock